Fudenberg H H
Neurolmmuno Therapeutics Research Foundation Spartanburg, S.C., USA.
Biotherapy. 1996;9(1-3):143-7. doi: 10.1007/BF02628672.
40 infantile autistic patients were studied. They ranged from 6 years to 15 years of age at entry. 22 were cases of classical infantile autism; whereas 18 lacked one or more clinical defects associated with infantile autism ("pseudo-autism"). Of the 22 with classic autism, 21 responded to transfer factor (TF) treatment by gaining at least 2 points in symptoms severity score average (SSSA); and 10 became normal in that they were main-streamed in school and clinical characteristics were fully normalized. Of the 18 remaining, 4 responded to TF, some to other therapies. After cessation of TF therapy, 5 in the autistic group and 3 of the pseudo-autistic group regressed, but they did not drop as low as baseline levels.
对40名患自闭症的儿童进行了研究。他们入院时的年龄在6岁至15岁之间。其中22例为典型的儿童自闭症；而另外18例则缺少一项或多项与儿童自闭症相关的临床缺陷（“假性自闭症”）。在22例典型自闭症患者中，21例对转移因子（TF）治疗有反应，症状严重程度评分平均值（SSSA）至少提高了2分；10例恢复正常，能够进入主流学校学习，临床特征也完全恢复正常。在其余18例中，4例对TF有反应，还有一些对其他疗法有反应。停用TF治疗后，自闭症组中有5例、假性自闭症组中有3例病情出现反复，但未降至基线水平。
